A PHASE IB/II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF GDC-0199 (ABT-199) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PATIENTS WITH B-CELL NON-HODGKIN’S LYMPHOMA (NHL) AND DLBCL - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE IB/II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF GDC-0199 (ABT-199) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PATIENTS WITH B-CELL NON-HODGKIN’S LYMPHOMA (NHL) AND DLBCL

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Genentech
Protocol Number
GO27878
Cancer Diagnosis
To Learn More Call
201-510-0910